The safety SUrvey of pneumonitis induced by the combination of platinum, pemetrexed and pembrolizumab in chemo-naive non-small cell lung cancer patient in the real-world setting.

The safety SUrvey of pneumonitis induced by the combination of platinum, pemetrexed and pembrolizumab in chemo-naive non-small cell lung cancer patient in the real-world setting. - SUSPECT study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038084

Enrollment

300

Registered

2019-10-01

Start date

2019-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-squamous Non-Small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Advanced non-squamous non-cell lung cancer patients (relapsed or stage III, IV) 2)Patients without mutated EGFR and ALK translocation. 3)Patients who received platinum / pemetrexed / pembrolizumab combination therapy as 1st-line treatment between 2018/12/21 and 2019/6/30.

Exclusion criteria

Exclusion criteria: Nothing

Design outcomes

Primary

Measure	Time frame
co-primary The incidence rate of pneumonitis within 90 days after the start of KN 189 regimen If the frequency is above a certain level, treatment for pneumonitis and prognostic factors will be investigated through central imaging.	—

Countries

Japan

Contacts

Public ContactDaichi Fujimoto

Kobe city medical center general hospital Division of pulmonary medicine

daichianzen@yahoo.co.jp078-302-4321

Outcome results